| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050730656 |
| P356 | DOI | 10.1038/JID.2010.126 |
| P932 | PMC publication ID | 4004181 |
| P698 | PubMed publication ID | 20505744 |
| P5875 | ResearchGate publication ID | 44633401 |
| P2093 | author name string | Karine A Cohen-Solal | |
| James S Goydos | |||
| Stephen A Rosenberg | |||
| Adam S Nabatian | |||
| Joseph L-K Chan | |||
| Kim T Merrigan | |||
| Maithao N Le | |||
| P2860 | cites work | Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel | Q24298654 |
| Treatment of metastatic melanoma: an overview | Q24642384 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma | Q28290954 | ||
| Metabotropic glutamate receptors (mGlus) and cellular transformation | Q30487265 | ||
| A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma | Q33616544 | ||
| Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation | Q33786919 | ||
| Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma | Q35141769 | ||
| Identification and functional roles of metabotropic glutamate receptor-interacting proteins | Q35764025 | ||
| Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system | Q35821619 | ||
| Advances in clinical trials for amyotrophic lateral sclerosis | Q36022219 | ||
| The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma | Q36170391 | ||
| Diagnosis and treatment of cutaneous melanoma: state of the art 2006. | Q36819323 | ||
| The future of tyrosine kinase inhibitors: single agent or combination? | Q37258971 | ||
| Genetic subgrouping of melanoma reveals new opportunities for targeted therapy | Q37436761 | ||
| Novel therapeutics for the treatment of metastatic melanoma | Q37486788 | ||
| Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37488998 | ||
| Treatment for metastatic malignant melanoma: old drugs and new strategies | Q37603597 | ||
| Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon | Q40348200 | ||
| Focal adhesion kinase promotes the aggressive melanoma phenotype. | Q40355320 | ||
| Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways | Q44266379 | ||
| Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). | Q44586345 | ||
| New ideas for therapy in ALS. | Q46612559 | ||
| Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia | Q48250298 | ||
| U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. | Q53754222 | ||
| A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. | Q55034186 | ||
| Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) | Q58255477 | ||
| A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers | Q77422002 | ||
| Riluzole for ALS: what is the evidence? | Q95785711 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell migration | Q189092 |
| P304 | page(s) | 2240-2249 | |
| P577 | publication date | 2010-05-27 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells | |
| P478 | volume | 130 |
| Q49907440 | A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma |
| Q33560677 | Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression |
| Q93109246 | Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma |
| Q98226242 | Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent |
| Q37626431 | Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells |
| Q92640761 | Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup |
| Q38681744 | Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer |
| Q36409682 | Functional effects of GRM1 suppression in human melanoma cells |
| Q37121338 | Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications |
| Q39168954 | Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies |
| Q30570451 | Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells |
| Q38971337 | Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas |
| Q34904277 | Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes |
| Q35122078 | Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer |
| Q36170150 | Molecular pathways: dysregulated glutamatergic signaling pathways in cancer |
| Q34450728 | Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma |
| Q36288488 | Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole |
| Q91596457 | Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice |
| Q33697210 | RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion |
| Q34525011 | Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. |
| Q47986792 | Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer. |
| Q30528073 | Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells |
| Q37608810 | Studies of Secondary Melanoma on C57BL/6J Mouse Liver Using 1H NMR Metabolomics |
| Q42009322 | Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression |
| Q36506697 | Targeting Wnt pathways in disease |
| Q64100930 | The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, and |
| Q38139096 | Therapeutic strategies impacting cancer cell glutamine metabolism |
| Q36997763 | Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma |
| Q52312423 | [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?] |
Search more.